Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Devyser Gains CE Mark for NGS Hereditary Breast and Ovarian Cancer Test

Devyser Gains CE Mark for NGS Hereditary Breast and Ovarian Cancer Test

Jul 22, 2020
|
staff reporter

NEW YORK – Swedish genetic test developer Devyser announced Wednesday it has received CE marking for its next-generation sequencing-based hereditary breast and ovarian cancer assay.

The targeted sequencing test analyzes 12 genes and uses a proprietary amplification-based library preparation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Featured Webinar

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

Dec
01
Featured Webinar

Post-Transplant Viral Load Monitoring: Improving Practices and Clinical Considerations

Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

What's Popular?

In Cancer

  1. Biodesix Prices $72M IPO

  2. Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC

  3. Exact Sciences Aiming to Make Pan-Cancer Blood Screening Part of Standard Medical Care

    Premium

  4. UPDATE: Biocartis, Exact Sciences Terminate Oncotype DX Agreement

  5. Strata Oncology Receives Medicare Coverage for NGS Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.